Alcaraz A - Search Results

1

Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.

Elhilali M, Emberton M, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Alcaraz A, Vallancien G; ALF-ONE Study Group. Elhilali M, et al. Among authors: alcaraz a. BJU Int. 2006 Mar;97(3):513-9. doi: 10.1111/j.1464-410X.2005.05962.x. BJU Int. 2006. PMID: 16469018

2

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.

van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, Alcaraz A, Vallancien G; ALF-ONE Study Group. van Moorselaar RJ, et al. Among authors: alcaraz a. BJU Int. 2005 Mar;95(4):603-8. doi: 10.1111/j.1464-410X.2005.05347.x. BJU Int. 2005. PMID: 15705088 Clinical Trial.

3

Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.

Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, Alcaraz A, Vallancien G; Alf-One Study Group. Emberton M, et al. Among authors: alcaraz a. Urology. 2005 Aug;66(2):316-22. doi: 10.1016/j.urology.2005.03.024. Urology. 2005. PMID: 16098361

4

Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.

Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G; ALF-ONE Study Group. Hartung R, et al. Among authors: alcaraz a. J Urol. 2006 Feb;175(2):624-8; discussion 628. doi: 10.1016/S0022-5347(05)00155-2. J Urol. 2006. PMID: 16407011

5

Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G. Emberton M, et al. Among authors: alcaraz a. J Urol. 2006 Sep;176(3):1051-6. doi: 10.1016/j.juro.2006.04.044. J Urol. 2006. PMID: 16890690

6

Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.

Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M; ALF-ONE Study Group. Vallancien G, et al. Among authors: alcaraz a. BJU Int. 2008 Apr;101(7):847-52. doi: 10.1111/j.1464-410X.2008.07458.x. BJU Int. 2008. PMID: 18321317

7

The influence of family history on prostate cancer risk: implications for clinical management.

Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schröder FH, Tubaro A. Madersbacher S, et al. Among authors: alcaraz a. BJU Int. 2011 Mar;107(5):716-721. doi: 10.1111/j.1464-410X.2010.10024.x. Epub 2010 Dec 16. BJU Int. 2011. PMID: 21166744 Review.

8

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group. Azzouzi AR, et al. Among authors: alcaraz a. Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20. Lancet Oncol. 2017. PMID: 28007457 Free article. Clinical Trial.

9

Efficacy and safety of a hexanic extract of Serenoa repens (Permixon^® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.

Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero García JM, Fernández-Pro Ledesma A, Cózar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V. Vela-Navarrete R, et al. Among authors: alcaraz a. BJU Int. 2018 Dec;122(6):1049-1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6. BJU Int. 2018. PMID: 29694707 Free article.

10

Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer.

Alcaraz A, Corral JM, Ribal MJ, Mallofré C, Mengual L, Carrió A, Gil-Vernet Sedó JM, Villavicencio H. Alcaraz A, et al. BJU Int. 2004 Aug;94(3):407-11. doi: 10.1111/j.1464-410X.2004.04829.x. BJU Int. 2004. PMID: 15291877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

624 results

Search Page

Filters